to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\. Confirmed diagnosis of autoimmune bullous disease;
* 2\. Age ≥18 years, regardless of gender;
* 3\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements.
Exclusion Criteria:
* 1\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation;
* 2\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy;
* 3\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336;
* 4\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.
Primary outcome measure(s)
To evaluate the efficacy after CM336 treatment — Up to 52 weeks Proportion of subjects in sustained complete remission
Trial sites (1)
Facility
City
Region
Status
Dermatology Hospital Affiliated to Shandong First Medical University
Jinan
China
Recruiting
More Shandong First Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.